Biotech stocks have been outperforming the broader market over the past three months, driven by optimism regarding potential rate cuts. The Fed is expected to start cutting rates later this month, and...
/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts remain bullish on the stock’s prospects.
These exchange-traded funds can help you easily tap into some promising growth opportunities.
/Gilead%20Sciences%2C%20Inc_%20logo%20and%20vials%20-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Gilead Sciences is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.
You don't need to be a stock market expert to earn above-average returns.
/Regeneron%20Pharmaceuticals%2C%20Inc_%20pharmaceuticals%20by-%20okskaz%20via%20iStock.jpg)
Regeneron Pharmaceuticals has outperformed the broader market over the past year, and Wall Street analysts are optimistic about the stock’s outlook.
If you invest over the long term, you'll increase your chances of victory.
Moderna stock continues to sag, even as new COVID variants emerge. However, investors may be underestimating the potential of the mRNA pipeline.
As the IBB ETF nears a potential breakout, watch for strong performers like Regeneron Pharmaceuticals, Vertex, and Exelixis to continue outperforming.
These exchange-traded funds (ETFs) offer low or ultralow net expense ratios and are perfectly positioned to help investors grow their wealth.